Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Type
Public
HQ
Exton, US
Size (employees)
52 (est)
Fibrocell Science is headquartered in Exton, US

Key People at Fibrocell Science

Robert S. Langer

Robert S. Langer

Director
John Maslowski

John Maslowski

Vice President, Scientific Affairs

Fibrocell Science Office Locations

Fibrocell Science has an office in Exton
Exton, US (HQ)
405 Eagleview Boulevard

Fibrocell Science Data and Metrics

Fibrocell Science Financial Metrics

Fibrocell Science's revenue was reported to be $355 k in 2016
USD

Revenue (Y, 2016)

355 k

Revenue growth (Y, 2015 - Y, 2016), %

(28%)

Gross profit (Y, 2016)

(342 k)

Gross profit margin (Y, 2016), %

(96%)

Net income (Y, 2016)

(15.3 m)

EBIT (Y, 2016)

(26.5 m)

Market capitalization (26-Jun-2017)

50.7 m

Closing share price (26-Jun-2017)

3.4

Cash (31-Dec-2016)

17.5 m
Fibrocell Science's current market capitalization is $50.7 m.
USDFY, 2013FY, 2014FY, 2015Y, 2016

Revenue

200 k180 k492 k355 k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

722 k697 k

Gross profit

(230 k)(342 k)

Gross profit Margin, %

(47%)(96%)

EBIT

(37.4 m)(26.5 m)

EBIT margin, %

(7603%)(7459%)

Interest income

8 k

Pre tax profit

(34.5 m)(15.3 m)

Net Income

(30.6 m)(25.7 m)(34.5 m)(15.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

60 m37.5 m29.3 m17.5 m

Inventories

1.2 m1.3 m1.2 m513 k

Current Assets

61.9 m39.3 m31 m18 m

PP&E

1.7 m1.6 m1.6 m1.5 m

Total Assets

69 m45.6 m36.7 m19.6 m

Accounts Payable

3 m1.1 m499 k440 k

Current Liabilities

3.6 m3.5 m15.4 m3 m

Additional Paid-in Capital

167.3 m143.1 m161.3 m170.4 m

Retained Earnings

(102.7 m)(112.7 m)(147.2 m)(162.6 m)

Total Equity

64.7 m14.2 m7.9 m

Financial Leverage

1.1 x2.6 x2.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(30.6 m)(25.7 m)(34.5 m)(15.3 m)

Depreciation and Amortization

863 k883 k767 k564 k

Accounts Receivable

54 k12 k9 k12 k

Inventories

(120 k)26 k35 k796 k

Accounts Payable

2 m(1.8 m)(114 k)(139 k)

Cash From Operating Activities

(20.1 m)(22.3 m)(24.1 m)(29.4 m)

Purchases of PP&E

(360 k)(242 k)(271 k)(253 k)

Cash From Investing Activities

(360 k)(242 k)(245 k)(252 k)

Cash From Financing Activities

49.1 m16.1 m17.9 m
USDY, 2016

Revenue/Employee

6.8 k

Financial Leverage

2.5 x

Fibrocell Science Market Value History

Fibrocell Science Online and Social Media Presence

Fibrocell Science Company Life and Culture

You may also be interested in